- Home
- TRGP vs REGN Comparison
TRGP vs REGN Comparison
Compare TRGP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRGP | REGN |
|---|---|---|
| Founded | 2005 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.7B | 68.8B |
| IPO Year | 2010 | 1995 |
Fundamental Metrics
Financial Performance| Metric | TRGP | REGN |
|---|---|---|
| Price | $290.05 | $827.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 25 |
| Target Price | $257.29 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 1.1M | 565.1K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.00% | 0.55% |
| EPS Growth | ★ 47.91 | 8.19 |
| EPS | 5.75 | ★ 18.95 |
| Revenue | ★ $17,028,300,000.00 | $5,872,227,000.00 |
| Revenue This Year | $30.33 | $12.45 |
| Revenue Next Year | $6.55 | $10.13 |
| P/E Ratio | $51.12 | ★ $44.35 |
| Revenue Growth | 3.95 | ★ 20.82 |
| 52 Week Low | $144.14 | $541.00 |
| 52 Week High | $307.94 | $859.34 |
Technical Indicators
Market Signals| Indicator | TRGP | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 65.31 |
| Support Level | $254.47 | $732.04 |
| Resistance Level | $307.94 | $847.00 |
| Average True Range (ATR) | 7.66 | 19.34 |
| MACD | 0.23 | -3.02 |
| Stochastic Oscillator | 58.99 | 76.33 |
Price Performance
Historical ComparisonAbout TRGP Targa Resources Inc.
Targa Resources Corp is a midstream firm that mainly operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset. It has two operating segments: Gathering and Processing, and, Logistics and Transportation (also referred to as the Downstream Business).
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.